TOP 10 COMPANIES IN EUROPE CANCER DIAGNOSTICS MARKET

The Europe Cancer Diagnostics Market will grow at a CAGR of 5.6% during the forecast period to reach $12.21 billion by 2031. Cancer diagnosis comprises a number of in vitro diagnostics and imaging tests used to diagnose different kinds of cancer, such as breast cancer, lung cancer, prostate cancer, colorectal cancer, and other cancer types. These tests are used to identify any indication of cancer, guide treatment decisions, predict the risk of cancer recurrence, track treatment effectiveness, and characterize its type and stage. This report provides a market assessment of products used for cancer diagnosis, which includes kits & reagents, imaging instruments, and IVD instruments, among others.

The growth of this market is driven by the rising prevalence of cancer, supporting initiatives for early cancer diagnosis, creating awareness, increasing investments and funding for cancer research, and technological advancements. Additionally, supporting initiatives toward precision diagnostics for cancer are expected to generate growth opportunities for the players operating in the Europe cancer diagnostics market and are expected to offer significant market growth opportunities.

Here are the top 10 companies operating in the Europe Cancer Diagnostics Market

Thermo Fisher Scientific Inc. (U.S.)

Founded in 1956 and headquartered in Massachusetts, U.S., Thermo Fisher Scientific Inc. is a biotechnology company engaged in life sciences research. The company operates through four reportable segments: Life Science Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products & Biopharma Services. The company operates in the cancer diagnostics market through the Life Sciences Solutions and the Specialty Diagnostics segments by providing cancer diagnostics reagents, instruments, and consumables. The company offers products to pharmaceutical and biotechnology companies, hospitals and clinical diagnostic labs, universities, research institutions, and government agencies, as well as environmental, industrial, and food research and development companies. Some major brands of Thermo Fisher are Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon, and PPD.

The company has a direct presence through its regional offices and production sites in the U.S., Mexico, Brazil, Germany, Belgium, Austria, the U.K., Italy, the Netherlands, South Africa, the UAE, India, China, Japan, Australia, and the Republic of Korea. Some of its subsidiaries operating in the cancer diagnostics market are Thermo Fisher Scientific C.V. (Netherlands), Thermo Electron A/S (France), Fisher Germany Limited & Co. KG (Germany), Fisher Scientific (Austria) GmbH (Austria), and Fisher Scientific Europe Holdings B.V. (Netherlands).

F. Hoffmann-La Roche Ltd (Switzerland)

Founded in 1896 and headquartered in Basel, Switzerland, F. Hoffmann-La Roche Ltd is a healthcare company that develops, manufactures, and markets a wide range of healthcare solutions. The company operates through two reportable divisions, namely Pharmaceuticals and Diagnostics. The company operates in the cancer diagnostics market through the Diagnostics segment by providing kits, reagents, and immunoassay analyzers, among others.

The company has a geographical presence across the U.S., Germany, Austria, Canada, Belgium, Denmark, Estonia, Finland, France, Italy, the Netherlands, Switzerland, Japan, China, India, New Zealand, Australia, Latin America, and Africa. Furthermore, the company has 20 manufacturing sites and 33 research and development sites worldwide.

Some of its subsidiaries are Diagnostics GmbH (Germany), Roche Diagnostics S.p.A. (Italy), Roche Diagnostics France SAS (France), Roche Diagnostics Limited (U.K.), Roche Diagnostics International AG (Switzerland), Roche Diabetes Care Deutschland GmbH (Germany), and Roche Diagnostics (Hellas) S.A. (Greece).

QIAGEN N.V. (Netherlands)

Founded in 1984 and headquartered in Venlo, Netherlands, QIAGEN N.V. develops and sells instruments, consumables, and digital bioinformatics solutions for oncology, infectious diseases, sexual & reproductive health, TB management, precision diagnostics, and point-of-care testing research. The company operates in two business segments: Molecular Diagnostics and Life Sciences. The company operates in the cancer diagnostics market through the Molecular Diagnostics segment by providing IVD kits, reagents, and assays.

QIAGEN offers its products to more than 500,000 customers and has 35 subsidiaries operating across 25 countries through sales and manufacturing offices and operational sites, including the U.S., Canada, Germany, Spain, the U.K., France, Italy, the Netherlands, Sweden, Turkey, Sweden, Brazil, Mexico, China, Hong Kong, Taiwan, South Korea, India, and South Africa. Qiagen has manufacturing and production facilities in the U.S., Germany, China, and the U.K.

The company has a strong distribution network through its partners across 60 countries worldwide, and some of the subsidiaries operating in the cancer diagnostics market are QIAGEN AG (Switzerland), QIAGEN Ltd. (U.K.), QIAGEN France S.A.S. (France), QIAGEN AG (Switzerland), QIAGEN Deutschland Holding GmbH (Germany), QIAGEN S.r.l (Italy), and QIAGEN Finance Ltd. (Ireland).

Abbott Laboratories (U.S.)

Incorporated in 1900 and headquartered in Illinois, U.S., Abbott Laboratories is a healthcare company that develops, manufactures, and sells healthcare products. The company offers various products in diagnostics, medical devices, nutrition, and branded generic pharmaceuticals markets. Abbott operates worldwide through four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices.

The Diagnostic Products business segment is further divided into Core Laboratory Diagnostics, Rapid Diagnostics, Point of Care Diagnostics, and Molecular Diagnostics business segments. The company operates in the cancer diagnostics market through the Core Laboratory Diagnostics and Molecular Diagnostics business segments. The company offers tests, kits, and panels for cancer testing.

Abbott has a wide geographic presence and a strong distribution network through direct and indirect channels across North America, Europe, Latin America, Asia–Pacific, and the Middle East & Africa. The company has 88 manufacturing facilities globally, of which 24 manufacturing sites are engaged in developing diagnostic products. Some of its subsidiaries operating in the cancer diagnostics market include Abbott Diagnostics GmbH (Germany), Abbott Products Unlimited Company (Ireland), Abbott Medical France SAS (France), and Abbott Medical GmbH.

Illumina, Inc. (U.S.)

Incorporated in 1998 and headquartered in California, U.S., Illumina, Inc. is a biotechnology company that provides sequencing and array-based solutions for genomic and genetic analysis. The company operates through two reportable segments, namely Core Illumina and GRAIL. The company operates in the cancer diagnostics market through both segments by providing cancer diagnostics kits, reagent panels, and instruments.

In August 2021, Illumina, Inc. acquired the GRAIL (U.S.) to speed up patient access to multi-cancer early-detection tests. Illumina provides its products to government laboratories, genomic research centers, academic institutions, hospitals, commercial molecular diagnostics laboratories, and pharmaceutical and consumer genomics companies. The company has a direct presence through manufacturing sites, research and development sites, offices, and laboratories in the U.S., Germany, New Zealand, China, France, Japan, the Netherlands, Korea, Israel, Singapore, and the U.K.

Illumina distributes its products globally in North America, Europe, Latin America, Asia-Pacific, and the Middle East & Africa through its distributors. Some of its subsidiaries operating in the cancer diagnostics market are Illumina Netherlands B.V. (Netherlands), Grail Bio UK Limited (U.K.), Illumina GmbH (Germany), Illumina UK, Ltd. (U.K.), Illumina Italy S.r.l. (Italy), and Illumina Austria GmbH (Austria).

Meticulous Research in its latest publication on Europe Cancer Diagnostics Market has predicted the growth of 5.6% during the forecast year 2024-2031.

Canon Medical Systems Corporation (Japan)

Founded in 1930 and headquartered in Tochigi, Japan, Canon Medical Systems Corporation is a technology company that manufactures laser printers, office multi-function devices (MFDs), inkjet printers, cameras, medical equipment, and lithography equipment. The company operates through four business units, namely Printing, Imaging, Medical, and Industrial. Canon operates in the cancer diagnostics market through its Medical Business Unit segment by providing diagnostic imaging systems.

The company has a geographical presence in the Americas, Japan, Europe, Asia, and Oceania and has a total of 57 manufacturing sites, offices, and R&D facilities across these regions. Some of its subsidiaries operating in the cancer diagnostics market are Canon France S.A.S. (France), Canon Italia S.p.A. (Italy), Canon Medical Systems Ltd. (U.K.), and Canon Medical Systems Europe (Netherlands).

Siemens Healthineers AG (Germany)

Founded in 1847 and headquartered in Erlangen, Germany, Siemens Healthineers AG is a healthcare solutions and services company that develops, designs, produces, and distributes imaging systems, clinical and workflow systems and solutions, and systems for minimally invasive treatments. Siemens provides advanced therapeutic devices and products for image-guided cancer treatments, cardiology, and surgery.

The company operates through four reportable segments: Imaging, Diagnostics, Varian, and Advanced Therapies. The company operates in the cancer diagnostics market through three segments, namely Imaging, Diagnostics offering imaging systems, scanners, cancer tests, and reagents for cancer diagnosis.

The company offers diagnostic products to public and private healthcare providers such as clinics, laboratories, hospitals, joint medical practices/physicians, universities, and public health agencies. The company has a geographical presence in more than 70 countries with production facilities and R&D sites in Europe, the Middle East & Africa, the U.S., Germany, China, India, and Australia.

Some of its subsidiaries operating in the cancer diagnostics market are Siemens Healthcare GmbH (Germany), Varian Medical Systems France SARL (France), Varian Medical Systems Nederland B.V (Netherlands), Varian Medical Systems Finland OY, Helsinki (Finland), Varian Medical Systems Gesellschaft mbH (Austria), and Varian Medical Systems Iberica SL, Madrid (Spain) among others.

GE HealthCare Technologies Inc. (U.S.)

Founded in 2023 as a separate entity after the spin-off from General Electric Company. The company is headquartered in Illinois, U.S., and is a diagnostics, medical technology, and digital solutions company. The company offers products, services, and complementary digital solutions for treating, diagnosing, and monitoring patients.

The company operates through four business segments: Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). GE HealthCare operates in the cancer diagnostics market through the Imaging, Ultrasound, and Pharmaceutical Diagnostics (PDx) segment by providing imaging instruments and consumables.

The company maintains a direct presence in more than 160 countries. It operates through 43 manufacturing sites situated across 17 countries and has R&D sites in 18 countries, including the U.S., Canada, China, France, Germany, the U.K., Israel, India, Brazil, Mexico, Sweden, Denmark, Austria, Germany, France, Norway, Japan, Ireland, and South Korea.

Some of its subsidiaries operating in the cancer diagnostics market are BK Medical UK Limited (U.K.), GE Healthcare B.V. (Netherlands), GE Healthcare Equipment Finance (France), GE Medical Systems Italia SpA (Italy), GE Medical Systems Information Technologies GmbH (Germany), and GE Medical Systems Limited (U.K.).).

Koninklijke Philips N.V. (Netherlands)

Founded in 1891 and headquartered in Amsterdam, Netherlands, Koninklijke Philips N.V. is a technology company that provides healthcare, consumer lifestyle, and lighting products. Its diverse portfolio encompasses products and services in various domains, including diagnostic imaging, patient monitoring and health informatics, image-guided therapy, as well as consumer health and home care.

The company operates through four business segments: Diagnosis & Treatment, Connected Care, Personal Health, and Other. The company operates in the cancer diagnostics market through the Diagnosis & Treatment segment by providing cancer diagnostics imaging systems and software. The Diagnosis & Treatment segment is further sub-segmented into Diagnostic Imaging, Ultrasound, Enterprise Diagnostic Informatics, and Image Guided Therapy.

Philips has a direct presence in North America, Western Europe, and other geographies through three market groups such as North America, Greater China, and International Markets. These groups are active in more than a hundred countries across the world. The company has real estate, R&D sites, and manufacturing facilities in the U.S., Canada, Germany, Italy, Spain, the U.K., Brazil, Mexico, New Zealand, Indonesia, Malaysia, Singapore, Philippines, Egypt, Iraq, Saudi Arabia, and Qatar. Some of its subsidiaries operating in the cancer diagnostics market are Philips Medical Systems DMC GmbH (Germany), Philips Technologies GmbH (Germany), Philips France (France), Philips Ibérica, S.A. (Spain), Philips U.K. Limited (U.K.), and Philips AG (Switzerland).

FUJIFILM Holdings Corporation. (U.S.)

Founded in 1934 and headquartered in Tokyo, Japan, FUJIFILM Holdings Corporation designs, manufactures, and markets healthcare solutions, imaging solutions, and document solutions. The company operates through four business segments: Healthcare, Business Innovation, Imaging, and Materials. FUJIFILM operates in the cancer diagnostics market through its Medical Systems segment (a subsegment of the Healthcare segment).

The company has manufacturing facilities in the U.S., Denmark, China, Southeast Asia, and the U.K., and office locations in North America, Latin America, Europe, the Middle East, Africa, Asia, and Oceania. As of March 2022, the company had 280 consolidated subsidiaries, and some of the subsidiaries operating in the cancer diagnostic market are FUJIFILM Europe GmbH (Germany), FUJIFILM Europe GmbH (Germany), FUJIFILM Europe GmbH (Switzerland), FUJIFILM Medical Systems Benelux N.V. (Belgium), and Fujifilm Finance Europe B.V. (Netherlands) among others.

Hologic, Inc. (U.S.)

Founded in 1985 and headquartered in Massachusetts, U.S., Hologic, Inc. is a medical technology company that develops, manufactures, and supplies medical imaging systems, diagnostics products, and surgical products. Hologic offers its products and solutions to clinical laboratories, hospitals, surgeons, and healthcare providers. The company operates through four business segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. Hologic operates in the cancer diagnostics market through its Breast Health and Diagnostics segment by providing cancer diagnostics instruments and software.

The company has a geographical presence in the U.K., Costa Rica, the U.S., Europe, Asia-Pacific, and other countries through manufacturing facilities and sales & service offices. Some of the subsidiaries operating in the cancer diagnostics market are Hologic Deutschland GmbH (Germany), Hologic IP LTD (U.K.), Hologic Medicor GmbH (Germany), Hologic Medicor Suisse GmbH (Switzerland)., SuperSonic Imagine GmbH (Germany), and SuperSonic Imagine SA (France).

Authoritative Research on the Europe Cancer Diagnostics Market – Opportunity Analysis and Industry Forecast (2024-2031)

Need more information? Meticulous Research®’s new report covers each of these companies in much more detail, providing analysis on the following:

• Recent financial performance
• Key products
• Significant company strategies
• Partnerships and acquisitions

The Comprehensive report provides global market size estimates, market share analysis, revenue numbers, and coverage of key issues and trends.